People · Operator
Named in public records as an officer, director or promoter · active 2016–2017 · Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TwinStrand Biosciences, Inc. | — | Biotech / Pharma | Series C | $85.0M | $132.2M | 2016 |
| Stasys Medical Corp. | — | Biotechnology | Seed | $1.4M | $55.6M | 2017 |
Linden Rhoads at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Linden Rhoads on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chris Igielski | 2 | 2 |
| Chad Waite | 1 | 11 |
| Steve Dow | 1 | 7 |
| Soma Somasegar | 1 | 5 |
| Michael Pellini | 1 | 4 |
| Jason Myers | 1 | 4 |
| Christopher Benoit | 1 | 3 |
| Jesse Salk | 1 | 3 |
| Mike Pellini | 1 | 3 |
| Ronnie Andrews | 1 | 2 |
| DAVID CANNER | 1 | 2 |
| Robert Barry | 1 | 2 |
| Nathan White | 1 | 2 |
| Michael Kranda | 1 | 2 |
| Kellie Bickel | 1 | 1 |
| Elena Cant | 1 | 1 |
| Michele Fernandes | 1 | 1 |
| Terry Myerson | 1 | 1 |
| Michael Rackley | 1 | 1 |
| Chad Waite, Jr. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.